Pharma

Your Article Summary

See Latest Articles

Study Showed VYVANSE (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Shire, 07/02/09

Shire plc, the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder. VYVANSE is the first approved stimulant for adults with ADHD to be evaluated in this setting, and these data were presented today at the 49th annual New Clinical Drug Evaluation Unit meeting in Hollywood, FL. VYVANSE is currently approved by the US Food and Drug Administration for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Myriad Genetics Acquires Exclusive Rights to Pancreatic Cancer Gene Patents From Johns Hopkins
Myriad, 10/16/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

See All of Research & Development